News Releases

- Completed I nitial P ublic O ffering of C ommon S tock, R aising G ross P roceeds of ~$ 181.9M - - Partial Response Confirmed in Glioblastoma Multiforme Patient in Phase 1 Trial of PRT811 - - Durable Complete Response Ongoing in HRD+ High Grade Serous Ovarian Cancer Patient in Phase 1 Trial of

WILMINGTON, Del., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the first patient has been dosed in its first-in-human Phase 1 open-label, multicenter, dose-escalation study of PRT1419 in

WILMINGTON, Del., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its initial public offering of 9,573,750 shares of common stock, including the full exercise of the underwriters’ option

WILMINGTON, Del., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its initial public offering of 8,325,000 shares of its common stock at a public offering price of $19.00 per share.

– Expands Board of Directors with Two New Appointments – Wilmington, DE – August 24, 2020 – Prelude Therapeutics, a privately-held, clinical-stage precision oncology company, today announced that it has completed a $50 million Series C financing round led by Prelude’s two existing institutional

– Advances lead product into clinic and additional compounds into preclinical development – David Mauro, MD, PhD, as Chief Medical Officer, and Brian Piper, MBA, as Chief Financial Officer, join management team led by Founder and CEO, Kris Vaddi, PhD Wilmington, DE – June 12, 2019 – Prelude